• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型候选基因的差异拷贝数异常与乳腺原位导管癌向浸润性导管癌的进展相关。

Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.

机构信息

Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

出版信息

Genes Chromosomes Cancer. 2012 Dec;51(12):1067-78. doi: 10.1002/gcc.21991. Epub 2012 Aug 9.

DOI:10.1002/gcc.21991
PMID:22887771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3465468/
Abstract

Only a minority of intraductal carcinomas of the breast give rise to stromally invasive disease. We microdissected 206 paraffin blocks representing 116 different cases of low-grade ductal carcinoma in situ (DCIS). Fifty-five were pure DCIS (PD) cases without progression to invasive carcinoma. Sixty-one cases had a small invasive component. DNA was extracted from microdissected sections and hybridized to high-density bacterial artificial chromosome arrays. Array comparative genomic hybridization analysis of 118 hybridized DNA samples yielded data on 69 samples that were suitable for further statistical analysis. This cohort included 20 pure DCIS cases, 25 mixed DCIS (MD), and 24 mixed invasive carcinoma samples. PD cases had a higher frequency of DNA copy number changes than MD cases, and the latter had similar DNA profiles compared to paired invasive carcinomas. Copy number changes on 13 chromosomal arms occurred at different rates in PD versus MD lesions. Eight of 19 candidate genes residing at those loci were confirmed to have differential copy number changes by quantitative PCR. NCOR2/SMRT and NR4A1 (both on 12q), DYNLRB2 (16q), CELSR1, UPK3A, and ST13 (all on 22q) were more frequently amplified in PD. Moreover, NCOR2, NR4A1, and DYNLRB2 showed more frequent copy number losses in MD. GRAP2 (22q) was more often amplified in MD, whereas TAF1C (16q) was more commonly deleted in PD. A multigene model comprising these candidate genes discriminated between PD and MD lesions with high accuracy. These findings suggest that the propensity to invade the stroma may be encoded in the genome of intraductal carcinomas.

摘要

仅有少数乳腺导管内癌会发展为间质浸润性病变。我们对 206 个石蜡块进行了微切割,代表了 116 个不同的低级别导管原位癌(DCIS)病例。其中 55 个为无浸润性癌进展的纯 DCIS(PD)病例。61 个病例有小的浸润性成分。从微切割的切片中提取 DNA,并与高密度细菌人工染色体阵列杂交。对 118 个杂交 DNA 样本的阵列比较基因组杂交分析产生了 69 个适合进一步统计分析的样本数据。该队列包括 20 个纯 DCIS 病例、25 个混合 DCIS(MD)和 24 个混合浸润性癌样本。PD 病例的 DNA 拷贝数变化频率高于 MD 病例,而后者的 DNA 图谱与配对的浸润性癌相似。PD 与 MD 病变中 13 条染色体臂上的拷贝数变化以不同的速率发生。位于这些位点的 19 个候选基因中的 8 个通过定量 PCR 证实存在差异拷贝数变化。NCOR2/SMRT 和 NR4A1(均位于 12q)、DYNLRB2(16q)、CELSR1、UPK3A 和 ST13(均位于 22q)在 PD 中扩增更为频繁。此外,NCOR2、NR4A1 和 DYNLRB2 在 MD 中更频繁地出现拷贝数缺失。GRAP2(22q)在 MD 中扩增更为频繁,而 TAF1C(16q)在 PD 中更为常见缺失。由这些候选基因组成的多基因模型可以准确地区分 PD 和 MD 病变。这些发现表明,侵袭间质的倾向可能编码在导管内癌的基因组中。

相似文献

1
Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.新型候选基因的差异拷贝数异常与乳腺原位导管癌向浸润性导管癌的进展相关。
Genes Chromosomes Cancer. 2012 Dec;51(12):1067-78. doi: 10.1002/gcc.21991. Epub 2012 Aug 9.
2
Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.广泛原位导管癌伴小灶浸润性导管癌:比较基因组杂交显示的基因相似性证据
Int J Cancer. 2000 Jan 1;85(1):82-6. doi: 10.1002/(sici)1097-0215(20000101)85:1<82::aid-ijc15>3.0.co;2-s.
3
Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).用于导管原位癌(DCIS)预后分层的寡基因特征验证。
Breast Cancer Res Treat. 2016 Jun;157(3):447-59. doi: 10.1007/s10549-016-3838-4. Epub 2016 Jun 1.
4
Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization.通过比较基因组杂交检测到的乳腺癌进展特定阶段的基因变化。
J Mol Med (Berl). 2009 Feb;87(2):145-52. doi: 10.1007/s00109-008-0408-1. Epub 2008 Oct 21.
5
Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.鉴定与 DCIS 向浸润性导管癌进展相关的拷贝数改变。
Breast Cancer Res Treat. 2012 Jun;133(3):889-98. doi: 10.1007/s10549-011-1835-1. Epub 2011 Nov 4.
6
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma to Invasive Ductal Carcinoma.非低级别导管癌进展为浸润性导管癌的全外显子组测序分析。
Clin Cancer Res. 2020 Jul 15;26(14):3682-3693. doi: 10.1158/1078-0432.CCR-19-2563. Epub 2020 Mar 27.
7
Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.同步导管原位癌和浸润性乳腺癌中具有可比性的癌症相关突变特征。
Cancer Rep (Hoboken). 2020 Jun;3(3):e1248. doi: 10.1002/cnr2.1248. Epub 2020 May 28.
8
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.有证据表明,在乳腺导管癌进展过程中,细胞的分子变化先于形态学改变出现。
Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.
9
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.导管原位癌(DCIS)和早期浸润性乳腺癌中的分子多样性。
Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007. Epub 2010 Jun 26.
10
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.对导管原位癌和匹配的相邻浸润性乳腺癌进行基因组和突变分析,揭示了肿瘤内遗传异质性和克隆选择。
J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

引用本文的文献

1
Identification and bioinformatics analysis of cilia-associated gene families in (Ciliophora, Hypotrichia).纤毛虫纲下毛目纤毛相关基因家族的鉴定及生物信息学分析
Front Microbiol. 2025 May 13;16:1486189. doi: 10.3389/fmicb.2025.1486189. eCollection 2025.
2
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.从导管原位癌到浸润性乳腺癌的进展:分子特征及临床意义。
Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.
3
Upregulation of CELSR1 expression promotes ovarian cancer cell proliferation, migration, and invasion.

本文引用的文献

1
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.HER2 和 TOP2A 作为预测标志物用于含蒽环类药物的化疗方案作为乳腺癌辅助治疗:一项个体患者数据的荟萃分析。
Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.
2
The genomic relationship between primary breast carcinomas and their nodal metastases.原发性乳腺癌与其淋巴结转移之间的基因组关系。
Cancer Invest. 2011 May;29(4):300-7. doi: 10.3109/07357907.2011.568564.
3
A new normalizing algorithm for BAC CGH arrays with quality control metrics.
CELSR1 表达上调促进卵巢癌细胞增殖、迁移和侵袭。
Med Oncol. 2023 Dec 9;41(1):10. doi: 10.1007/s12032-023-02232-1.
4
Archival single-cell genomics reveals persistent subclones during DCIS progression.存档单细胞基因组学揭示了 DCIS 进展过程中持续存在的亚克隆。
Cell. 2023 Aug 31;186(18):3968-3982.e15. doi: 10.1016/j.cell.2023.07.024. Epub 2023 Aug 15.
5
Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma.肺腺癌预后相关关键基因的生物信息学及综合分析
J Thorac Dis. 2021 Feb;13(2):1172-1186. doi: 10.21037/jtd-21-49.
6
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.乳腺癌间质液的高通量蛋白质组学:鉴定肿瘤亚型特异性血清相关生物标志物。
Mol Oncol. 2021 Feb;15(2):429-461. doi: 10.1002/1878-0261.12850. Epub 2021 Jan 4.
7
CELSR1 Acts as an Oncogene Regulated by miR-199a-5p in Glioma.CELSR1在胶质瘤中作为受miR-199a-5p调控的癌基因发挥作用。
Cancer Manag Res. 2020 Sep 23;12:8857-8865. doi: 10.2147/CMAR.S258835. eCollection 2020.
8
Omics Integration Analyses Reveal the Early Evolution of Malignancy in Breast Cancer.组学整合分析揭示乳腺癌恶性肿瘤的早期演变
Cancers (Basel). 2020 Jun 4;12(6):1460. doi: 10.3390/cancers12061460.
9
Genomic landscape of ductal carcinoma in situ and association with progression.导管原位癌的基因组景观及其与进展的关联。
Breast Cancer Res Treat. 2019 Nov;178(2):307-316. doi: 10.1007/s10549-019-05401-x. Epub 2019 Aug 17.
10
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.乳腺导管原位癌主动监测试验的回顾性替代方法。
Int J Cancer. 2020 Mar 1;146(5):1189-1197. doi: 10.1002/ijc.32362. Epub 2019 May 8.
一种带有质量控制指标的BAC CGH阵列新归一化算法。
J Biomed Biotechnol. 2011;2011:860732. doi: 10.1155/2011/860732. Epub 2011 Feb 21.
4
iGenomicViewer: R package for visualisation of high dimension genomic data.iGenomicViewer:用于可视化高维基因组数据的R包。
Int J Bioinform Res Appl. 2010;6(6):584-93. doi: 10.1504/IJBRA.2010.038739.
5
The molecular pathology of breast cancer progression.乳腺癌进展的分子病理学。
J Pathol. 2011 Jan;223(2):307-17. doi: 10.1002/path.2808. Epub 2010 Nov 16.
6
Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach.使用高分辨率全基因组分析方法鉴定转移性乳腺癌相关基因。
J Cancer Res Clin Oncol. 2011 May;137(5):795-809. doi: 10.1007/s00432-010-0937-1. Epub 2010 Aug 3.
7
Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.解析乳腺癌的转录网络:NR4A1 降低正常和乳腺癌细胞系的迁移能力。
Breast Cancer Res. 2010;12(4):R51. doi: 10.1186/bcr2610. Epub 2010 Jul 19.
8
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.CITED2和NCOR2在乳腺癌抗雌激素耐药性及进展中的作用
Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10.
9
Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.原发性乳腺癌与其前哨淋巴结及更远处淋巴结转移灶的基因组改变:一项比较基因组杂交研究
Genes Chromosomes Cancer. 2009 Dec;48(12):1091-101. doi: 10.1002/gcc.20711.
10
Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma.SMRT/NCoR2共抑制因子的缺失与多发性骨髓瘤中JAG2的过表达相关。
Cancer Res. 2009 May 15;69(10):4380-7. doi: 10.1158/0008-5472.CAN-08-3467. Epub 2009 May 5.